SUSTAINED RESPONSE IN A PHASE III STUDY OF SARILUMAB PLUS NONBIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS

被引：0
|
作者：
Fleischmann, Roy [1 ]
St John, Greg [2 ]
Kimura, Toshio [3 ]
Iglesias-Rodriguez, Melitza [4 ]
Rosner, Itzhak [5 ]
Burmester, Gerd R. [6 ,7 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA
[2] Regeneron Pharmaceut Inc, Med Affairs, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] Regeneron Pharmaceut Inc, Med Affairs, Med Analyt, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Sanofi Genzyme, Global Med Affairs, Cambridge, MA USA
[5] Bnai Zion Med Ctr, Div Allergy & Clin Immunol, Haifa, Israel
[6] Free Univ, Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[7] Humboldt Univ, Berlin, Germany
来源：
RHEUMATOLOGY | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
223
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
    Fleischmann, Roy
    St. John, Greg
    Kimura, Toshio
    Iglesias-Rodriguez, Melitza
    Rosner, Itzhak
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [2] SUSTAINED RESPONSE IN A PHASE 3 STUDY OF SARILUMAB PLUS NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS
    Fleischmann, R.
    St John, G.
    Kimura, T.
    Iglesias-Rodriguez, M.
    van Hoogstraten, H.
    Rosner, I
    Burmester, G. R.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 21 - 22
  • [3] Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
    Fleischmann, Roy
    van Adelsberg, Janet
    Lin, Yong
    Castelar-Pinheiro, Geraldo da Rocha
    Brzezicki, Jan
    Hrycaj, Pawel
    Graham, Neil M. H.
    van Hoogstraten, Hubert
    Bauer, Deborah
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) : 277 - 290
  • [4] Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity
    Fleischmann, Roy
    van Hoogstraten, Hubert
    Jayawardena, Shyamalie
    Mangan, Erin K.
    Ching, Daniel
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] CLINICAL REMISSION OUTCOMES WITH SARILUMAB PLUS CSDMARDS IN ACTIVE, MODERATE-TO-SEVERE RA PATIENTS WITH INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS
    Burmester, G.
    Hrycaj, P.
    Pacheco-Tena, C.
    van Hoogstraten, H.
    Mangan, E. K.
    Lin, Y.
    Bauer, D.
    Fay, J.
    Parrino, J.
    Kivitz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 727 - 728
  • [6] SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Walker, David
    Genovese, Mark C.
    Kalunian, Kenneth
    Gottenberg, Jacques-Eric
    de Vlam, Kurt
    Mozaffarian, Neelufar
    Bartok, Beatrix
    Matzkies, Franziska
    Gao, Jie
    Guo, Ying
    Tasset, Chantal
    Sundy, John S.
    Takeuchi, Tsutomu
    RHEUMATOLOGY, 2019, 58
  • [7] Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor
    Albattal, Basel M.
    ANNALS OF SAUDI MEDICINE, 2016, 36 (03) : 190 - 196
  • [8] Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis
    Genovese, Mark C.
    Mangan, Erin K.
    Kimura, Toshio
    Iglesias-Rodriguez, Melitza
    Huizinga, Tom W. J.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] Effectiveness and Safety of Tacrolimus in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-modifying Anti-rheumatic Drugs: The TREASURE Study
    Sheen, Dong Hyuk
    Hong, Seung Jae
    Lee, Sang Heon
    Lee, Hye Soon
    Chung, Won Tae
    Jiang, Hongsi
    Lee, Sungmin
    Yoo, Dae Hyun
    JOURNAL OF RHEUMATIC DISEASES, 2019, 26 (01): : 20 - 30
  • [10] Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    van Vollenhoven, R. F.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 430 - 430
12345